Ciclesonide


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: Inhalation Asthma As metered-dose aerosol (80 or 160 mcg/actuation): 160 mcg as a single or in 2 divided doses daily. Maintenance: 80 mcg once daily. Severe asthma: 320 mcg bid. Nasal Perennial and seasonal allergic rhinitis As spray (50 mcg/actuation): 200 mcg/day, given as 2 sprays in each nostril once daily.
Contraindications
Primary treatment of severe acute asthma or status asthmaticus where intensive measures are needed.
Special Precautions
Patient w/ active or quiescent pulmonary TB, fungal, viral or bacterial infections, unless adequately treated. Avoid abrupt withdrawal. Severe hepatic impairment. Pregnancy and lactation. Monitoring Parameters Monitor height of childn and adolescents on long term treatment w/ inhaled corticosteroids; signs/symptoms of adrenal insufficiency, ocular effects (e.g. cataracts, glaucoma).
Adverse Reactions
Bad taste, paradoxical bronchospasm, rash and eczema, application site reactions, cough, nausea, vomiting, headache, dysphonia, oral fungal infections. Systemic effects after prolonged use (e.g. Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in childn and adolescents, bone mineral density decrease, cataract, glaucoma). Rarely, immediate hypersensitivity reactions or contact dermatitis (nasal).
Drug Interactions
Increased risk of systemic side effects w/ concomitant ketoconazole, itraconazole, ritonavir, nelfinavir or other potent CYP3A4 inhibitors.
ATC Classification
R01AD13 - ciclesonide ; Belongs to the class of topical corticosteroids used for prophylaxis and treatment of allergic rhinitis.
R03BA08 - ciclesonide ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids.
Disclaimer: This information is independently developed by CIMS based on ciclesonide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in